HealthEquity, Inc. (HQY) Q4 2024 Earnings Call Transcript
https://seekingalpha.com/article/4679248-healthequity-inc-hqy-q4-2024-earnings-call-transcript?source=feed_sector_transcripts
Mar 19, 2024 - HealthEquity, Inc. (NASDAQ:NASDAQ:HQY) Q4 2024 Results Conference Call March 19, 2024 4:30 PM ETCompany ParticipantsRichard Putnam - Investor RelationsJon...
0
HealthEquity, Inc. (HQY) Q3 2024 Earnings Call Transcript
https://seekingalpha.com/article/4656211-healthequity-inc-hqy-q3-2024-earnings-call-transcript?source=feed_sector_transcripts
Dec 05, 2023 - HealthEquity, Inc. (NASDAQ:NASDAQ:HQY) Q3 2024 Earnings Conference Call December 5, 2023 4:30 PM ETCompany ParticipantsRichard Putnam - Investor...
0
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
https://www.zacks.com/stock/news/2196582/reasons-to-add-cardinal-health-cah-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196582
Dec 12, 2023 - Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
0
Here's Why You Should Retain McKesson (MCK) Stock for Now
https://www.zacks.com/stock/news/2197165/here-s-why-you-should-retain-mckesson-mck-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197165
Dec 13, 2023 - McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
0
Centene (CNC) Unveils its 2024 Projections: Key Takeaways
https://www.zacks.com/stock/news/2197185/centene-cnc-unveils-its-2024-projections-key-takeaways?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197185
Dec 13, 2023 - Centene's (CNC) board boosts its share buyback program with a new $4 billion fund.
0
Here's Why Investors Should Hold Elevance (ELV) Stock for Now
https://www.zacks.com/stock/news/2198071/here-s-why-investors-should-hold-elevance-elv-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198071
Dec 14, 2023 - Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.
0
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
https://www.zacks.com/stock/news/2197789/here-s-why-you-should-retain-glaukos-gkos-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197789
Dec 14, 2023 - Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
0
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
https://www.zacks.com/stock/news/2200159/dexcom-s-dxcm-g7-cgm-connects-with-tandem-s-insulin-pump?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200159
Dec 19, 2023 - Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
0
Molina (MOH) to Pay Lower Price for California Medicare Buyout
https://www.zacks.com/stock/news/2200048/molina-moh-to-pay-lower-price-for-california-medicare-buyout?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200048
Dec 19, 2023 - Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
0
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
https://www.zacks.com/stock/news/2200160/glaukos-gkos-idose-tr-gets-fda-nod-for-glaucoma-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200160
Dec 19, 2023 - The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
0
Page 1>